--- name: Pharma and biotech teams shortName: Pharma & biotech category: Publications organizations stage: selected stageLabel: Selected workflows navDescription: Keep evidence consistent across internal and outsourced writing. description: See how pharma and biotech publication teams use 7Scholar to align internal and agency work around traceable evidence. related: - publication-teams - medcomms-agencies - cros --- # Keep every contributor on the same scientific story. Give every contributor one evidence boundary and review trail. ## Outcome ### One story across handoffs Reduce narrative drift and repeated evidence questions. #### Control the source set Keep outside evidence out when required. #### Direct agencies clearly Share intent, not just files. #### Review with confidence See the support behind each claim. ## The current workflow ### Outsourced writing still needs sponsor context. #### The source boundary is hard to enforce Outside evidence can stay hidden until late review. #### Review starts without receipts Sponsors receive prose, not the context behind each claim. #### Approved narratives fragment Teams give the same evidence different emphasis. ## How it works ### Govern the path from evidence to draft. #### Set the evidence boundary Load approved study materials, literature, messages, and templates. #### Approve the narrative Align on structure, intent, and evidence roles before drafting. #### Inspect and hand off Review changes and source anchors, then export the cited deliverable. ## Why 7Scholar ### Oversight without rebuilding the work. > Scientific consistency that survives every handoff. #### Closed-corpus controls Keep outside material out when policy requires it. #### Dual traceability Separate formal citations from sponsor-file context. #### Human review by design Approve the structure and every change before sign-off. ## Where 7Scholar fits ### What works today—and what comes next. This is a bounded publication workflow, not a replacement for MLR, safety, or submission systems. #### Available now **Ready to explore** - Focused manuscript pilots - Evidence-restricted projects - Tracked changes and cited output #### On the horizon **Sequenced expansion** - Publication derivatives - Enterprise, MLR, and regulated controls ## Questions ### Can we use only approved sources? Yes. Evidence restrictions can exclude outside material from the cited deliverable. ### Does 7Scholar replace our agency? No. Sponsors and writers share a workspace; judgment and approval stay human. ### How is confidential data handled? Data is encrypted, EU personal data stays in the EEA, and project content never trains models.